27/01/2015 14:16:52 Free Membership Login

Merck News (NYSE:MRK)

DateTimeSource
Headline
01/26/20158:30AMBWMerck Announces CHMP Issues Positive Opinion for Investigational Antibiotic SIVEXTRO® (tedizolid phosphate)
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of the investigational antibiotic SIVEXTRO® (tedizolid phosphate) for the treatment... More...>>
01/22/20153:29PMBWMerck, on Behalf of its Wholly Owned Subsidiary, Cubist Pharmaceuticals, Announces Tender Offer for Cubist’s 2.50% Converti...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, on behalf of its wholly owned subsidiary Cubist Pharmaceuticals, Inc., today announced that, in connection with the completion of the acquisition of Cubist by Merck, Cubist has commenced a tender offer (the “Convertible Notes Tender Offer”) to repurchase... More...>>
01/21/20158:00AMBWMerck Completes Tender Offer to Acquire Cubist
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the successful completion of the tender offer for all of the outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) at a purchase price of $102.00 per share. As of the tender offer expiration yesterday, 58,039,667... More...>>
01/20/20155:45PMPRNUSDana Holding Set to Join the S&P MidCap 400
Dana Holding Set to Join the S&P MidCap 400 PR Newswire NEW YORK, Jan. 20, 2015 NEW YORK, Jan. 20, 2015 /PRNewswire/ -- Dana Holding Corp. (NYSE: DAN) will replace Cubist Pharmaceuticals Inc. (NASD: CBST) in the S&P MidCap 400 after the close of trading on Thursday, January 22. S&P 100 & 500 constituent... More...>>
01/14/20158:30AMPRNUSPractice Fusion Announces Positive Results of Population Health Vaccine Initiative Conducted in Collaboration with Merck
Practice Fusion Announces Positive Results of Population Health Vaccine Initiative Conducted in Collaboration with Merck Unique vaccine-focused program leads to significant relative increase in vaccines recorded on the country's largest cloud-based electronic health record (EHR) platform PR Newswire SAN FRANCISCO, Jan... More...>>
01/13/20158:00AMBWLilly, Merck Enter Collaboration Agreement to Research Immuno-Oncology Combination Regimens in Multiple Types of Cancer
Combinations of KEYTRUDA® (pembrolizumab) with Alimta® (pemetrexed), Cyramza® (ramucirumab), or necitumumab to be explored Merck (NYSE:MRK), known as MSD outside the US and Canada, and Eli Lilly and Company (NYSE:LLY) announced today an oncology clinical trial collaboration to evaluate the safety, tolerability and efficacy... More...>>
01/12/20157:00AMBWMerck Provides Update on Strategic Actions to Transform the Company & Build a Platform for Sustained Future Growth at the 33r...
KEYTRUDA, First FDA-Approved Anti-PD-1 Therapy, Filed and Launched Within Five Months Company Expects to Submit sBLA for KEYTRUDA in Mid-Year 2015 for Advanced Non-Small Cell Lung Cancer NDA Submission for Hepatitis C Combination Regimen, Grazoprevir/Elbasvir (MK-5172/MK-8742), Planned for First Half of 2015 Seven New... More...>>
01/09/20154:39PMDJNEbola Vaccines Ready for West Africa Tests This Month, Says WHO
By Andrew Morse ZURICH--Tests of two Ebola vaccines currently under development could begin in West Africa as early as the end of the month, a senior World Health Organization official said Friday. Dr. Marie-Paule Kieny, the WHO assistant director general for health systems and innovation, said at a news conference following... More...>>
01/09/20158:00AMBWMerck to Present at the 33rd Annual J.P. Morgan Healthcare Conference
Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, Merck’s chairman and chief executive officer, is scheduled to present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco on Jan. 12, 2015 at 4:00 p.m. PST (7:00 p.m. EST). Investors, analysts... More...>>
01/05/201511:40AMDJNEbola Vaccine Tests Resume
ZURICH--A Geneva hospital said Monday it was resuming tests of an experimental Ebola vaccine licensed by Merck & Co. after a three-week pause in the trial to assess reports of mild joint pain in volunteers. In a statement, the University Hospitals of Geneva said a second test group of 56 people will receive injections... More...>>
01/05/201511:06AMDJNEbola Vaccine Tests Resume
By Marta Falconi ZURICH--A Geneva hospital said Monday it was resuming tests of an experimental Ebola vaccine licensed by Merck & Co. after a three-week pause in the trial to assess reports of mild joint pain in volunteers. In a statement, the University Hospitals of Geneva said a second test group of 56 people will... More...>>
01/05/20158:00AMBWMerck to Hold Fourth-Quarter and Full-Year 2014 Sales and Earnings Conference Call on February 4
Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its fourth-quarter and full-year 2014 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EST on Wednesday, Feb. 4. During the call, company executives will provide an overview of Merck’s performance for... More...>>
12/22/20148:00AMGLOBENewLink Genetics, Merck Collaboration to Manufacture Ebola Vaccine Candidate Supported by $30 Million Government Award
AMES, Iowa and KENILWORTH, N.J., Dec. 22, 2014 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that the Biomedical Advanced Research and Development Authority (BARDA) of the United States Department of Health and Human... More...>>
12/19/20148:00AMBWMerck Begins Tender Offer to Acquire Cubist
Merck (NYSE:MRK), known as MSD outside the United States and Canada, is commencing today, through a subsidiary, a cash tender to purchase all outstanding shares of common stock of Cubist Pharmaceuticals, Inc. (NASDAQ:CBST). On Dec. 8, 2014, Merck announced its intent to acquire Cubist. Upon the successful closing of the... More...>>
12/18/20148:51AMDJNMerck Acquires OncoEthix for Up to $375 Million
By Angela Chen Merck & Co. acquired privately held OncoEthix for up to $375 million, its latest push into the oncology market as the pharmaceutical giant continues bolstering its research-and-development pipeline. OncoEthix is a Swiss-based biotechnology company specializing in oncology, or the study of cancer, one... More...>>
12/18/20147:30AMBWMerck Acquires OncoEthix, a Privately Held Oncology Company Developing Novel BET Inhibitors for Hematological and Solid Cancers
Acquisition Expands Merck’s Oncology Portfolio with Novel Oral BET Inhibitor, OTX015 Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that it has acquired, through a subsidiary, OncoEthix, a Swiss-based privately held biotechnology company specializing in oncology drug development... More...>>
12/12/20148:30PMPRNUSCUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over ...
CUBIST PHARMACEUTICALS INVESTOR ALERT: Faruqi & Faruqi, LLP Announces the Investigation of Cubist Pharmaceuticals, Inc. Over the Proposed Sale of the Company to Merck & Co. Inc. - CBST Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors... More...>>
12/10/20149:30AMBWMerck Announces Appointment of Dr. Julie Gerberding as Executive Vice President for Strategic Communications, Global Public P...
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Dr. Julie Gerberding, 59, as executive vice president for strategic communications, global public policy and population health, effective Dec. 15. In this newly created Executive Committee position, Gerberding, who most... More...>>
12/10/20148:45AMBWInternational Breast Cancer Study Group, Breast International Group & Merck Announce Opening of International PANACEA Study o...
Collaborative Trial is First to Investigate an Anti-PD-1 Therapy, Pembrolizumab, Combined with Trastuzumab Study to Explore Whether New Approach May Reverse Trastuzumab Resistance in Cancer with Significant Unmet Need The International Breast Cancer Study Group (IBCSG), Breast International Group (BIG), and Merck, known... More...>>
12/10/20148:30AMBWData Investigating KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Triple-Negative Breast ...
18.5 Percent Overall Response Rate Observed in KEYTRUDA-Treated Patients with This Aggressive Form of Breast Cancer Phase 2 Study Planned for the First Half of 2015 (KEYNOTE-086) Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today early study findings demonstrating an overall response... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nyse mrk150127 14:16